Dr. Adam Margolin is the CEO and co-founder of Flashpoint Therapeutics. With over 20 years of experience in cancer research and technology development, he has led some of the largest and most successful research organizations in these areas.
Before starting Flashpoint Therapeutics, Dr. Margolin was a Venture Partner at Khosla Ventures, where he led efforts in therapeutic platform company creation, investment diligence, board level strategic guidance, and served as CEO of the cancer cell therapy company NextVivo.
Dr. Margolin has held various prestigious positions throughout his career, including Chair and Professor of the Department of Genetics and Genomic Sciences, Director of the Icahn Institute for Data Science and Genomic Technology, and Senior Associate Dean of Precision Medicine at Mount Sinai. In these roles, he led an organization that rose to become the #3 ranked genetics department in the country, encompassing over 700 people and over $100M annual revenue. Concurrently, Dr. Margolin served as Chief of Data Science of Sema4. Prior to Mount Sinai, he was the Founding Director of the Computational Biology program at Oregon Health & Science University, where he was also promoted to the rank of Tenured Full Professor.
Dr. Margolin is also an internationally recognized researcher who has developed methods ranked among the most influential algorithms in the field of cancer computational biology. He obtained his PhD from Columbia University and performed his postdoctoral research at the Broad Institute of Harvard and MIT. He also holds a bachelor’s degree from the Wharton School of Business and a master’s degree in Computer Science from the University of Pennsylvania.